Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.97
MUSTANG BIO, INC. entered into Securities Purchase Agreement with single institutional accredited investor valued at up to $4.4 million in gross proceeds (effective 2023-10-26).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- single institutional accredited investor
- Value
- up to $4.4 million in gross proceeds
- Effective
- 2023-10-26
Exact text from the filing
On October 26, 2023, Mustang Bio, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with a single institutional accredited investor (the “ Investor ”) pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “ Registered Offering ”), (i) 920,000 shares (the “ Shares ”) of common stock of the Company, $0.0001 par value per share (the “ Common Stock ”), at a price per Share of $1.70 and (ii) pre-funded warrants (the “ Pre-funded Warrants ”) to purchase up to 1,668,236 shares of Common Stock, at a price per Pre-funded Warrant equal to $1.699, the price per Share, less $0.001..
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
MUSTANG BIO, INC. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at Wainwright was paid a cash fee equal to 7.0% of the gross proceeds received by the Company in the Of (effective 2023-10-09).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
- Value
- Wainwright was paid a cash fee equal to 7.0% of the gross proceeds received by the Company in the Of
- Effective
- 2023-10-09
Exact text from the filing
H.C. Wainwright & Co., LLC (“ Wainwright ”) acted as the exclusive placement agent in connection with the Offerings under an Engagement Letter, dated as of October 9, 2023, between the Company and Wainwright (the “ Engagement Letter ”).
View on SEC.gov